Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice

被引：0

作者：

Fedyanin, M. ^{[1
]}

Elsnukaeva, H. ^{[1
]}

Demidova, I. ^{[2
]}

Stroyakovskiy, D. ^{[3
]}

Shelygin, Y. ^{[4
]}

Tsukanov, A. ^{[5
]}

Panina, M. ^{[6
]}

Moiseenko, F. ^{[7
]}

Karpenko, E. ^{[8
]}

Bolotina, L. ^{[8
]}

Kudryavtseva, A. ^{[9
]}

Filipenko, M. ^{[10
]}

Oskorbin, I. ^{[10
]}

Vladimirova, L. Y. ^{[11
]}

Timoshkina, N. N. ^{[12
]}

Kit, O. I. ^{[13
]}

Stroganova, A. ^{[14
]}

Dranko, S. ^{[14
]}

Tryakin, A. ^{[1
]}

Tjulandin, S. ^{[1
]}

机构：

[1] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Clin Pharmacol & Chemotherapy, Moscow, Russia

[2] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Genet, Moscow, Russia

[3] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Chemotherapy, Moscow, Russia

[4] Minister Hlth, State Sci Ctr Coloproctol, Moscow, Russia

[5] Minister Hlth, State Sci Ctr Coloproctol, Genet, Moscow, Russia

[6] Minister Hlth, State Sci Ctr Coloproctol, Oncol Dept, Moscow, Russia

[7] St Petersburg Clin Res & Pract Ctr Specialized Ty, Oncol, St Petersburg, Russia

[8] Minist Hlth Russian Federat RF, Branch Natl Med Res Radiol Ctr, RA Hertsen Moscow Oncol Res Inst, Chemotherapy, Moscow, Russia

[9] Russian Acad Sci, EIMB Engelhardt Inst Mol Biol, Lab Postgen Studies, Moscow, Russia

[10] Inst Clin Biol & Fundamental Med, Genet, Novosibirsk, Russia

[11] Natl Med Res Ctr Oncol, Med Oncol Dept, Rostov Na Donu, Russia

[12] Natl Med Res Ctr Oncol, Lab Mol Oncol, Rostov Na Donu, Russia

[13] Natl Med Res Ctr Oncol, Rostov Na Donu, Russia

[14] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Genet, Moscow, Russia

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.969

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448P

引用

页码：S557 / S558

页数：2

共 50 条

[21] Trecc: Re-challenge therapy with anti-EGFR in metastatic colorectal adenocarcinoma (mCRC).
Karani, Amanda
Felismino, Tiago
Diniz, Lara Azevedo
Macedo, Mariana Petaccia
Machado, Larissa
Sales, Diogo De Brito
Mello, Celso Lopes
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[22] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
Yamazaki, Kentaro
Yoshino, Takayuki
Tsuchihara, Katsuya
Shinozaki, Eiji
Muro, Kei
Nishina, Tomohiro
Yamaguchi, Kensei
Akagi, Kiwamu
Yuki, Satoshi
Yamanaka, Takeharu
Nomura, Shogo
Fujii, Satoshi
Esumi, Hiroyasu
Abe, Yukiko
Ohtsu, Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[23] Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
Yuki, Satoshi
Yoshino, Takayuki
Tsuchihara, Katsuya
Shinozaki, Eiji
Muro, Kei
Nishina, Tomohiro
Yamaguchi, Kensei
Akagi, Kiwamu
Yamazaki, Kentaro
Yamanaka, Takeharu
Nomura, Shogo
Fujii, Satoshi
Esumi, Hiroyasu
Abe, Yukiko
Ohtsu, Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue
Silvestris, Nicola
Tommasi, Stefania
Santini, Daniele
Russo, Antonio
Simone, Gianni
Petriella, Daniela
Maiello, Evaristo
Tonini, Giuseppe
Colucci, Giuseppe
EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (05) : 565 - 577
[25] Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).
Burge, Matthew E.
Wong, Hui-Li
Lee, Belinda
Tie, Jeanne
Kosminder, Suzanne
Field, Kathryn Maree
Tran, Ben
Desai, Jayesh
Ananda, Sumitra
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[26] Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
Chong, Li Chia
Hardingham, Jennifer E.
Townsend, Amanda R.
Piantadosi, Cynthia
Rico, Gonzalo Tapia
Karapetis, Chris
Padbury, Rob
Maddern, Guy
Roy, Amitesh
Price, Timothy J.
TARGETED ONCOLOGY, 2020, 15 (06) : 751 - 757
[27] Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
Li Chia Chong
Jennifer E. Hardingham
Amanda R. Townsend
Cynthia Piantadosi
Gonzalo Tapia Rico
Chris Karapetis
Rob Padbury
Guy Maddern
Amitesh Roy
Timothy J. Price
Targeted Oncology, 2020, 15 : 751 - 757
[28] Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
Idowu, Michael O.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (02) : 155 - 155
[29] Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma
Kamel-Reid, Suzanne
Zhang, Tong
Persons, Diane L.
Nikiforova, Marina N.
Halling, Kevin C.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (01) : 26 - 32
[30] Beyond KRAS:Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
Alfonso De Stefano
Chiara Carlomagno
World Journal of Gastroenterology, 2014, (29) : 9732 - 9743

← 1 2 3 4 5 →